Skylight Psychedelics Competitors

We are Compass, a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care. We believe people living with mental health conditions deserve the possibility of a better future. Our initial focus is advancing COMP360, a proprietary, investigational synthetic psilocybin treatment being evaluated for treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD). Our goal is to advance treatments that move the field of psychiatry towards treatment options that offer rapid onset and sustained durability, with infrequent dosing. We’re driven by our purpose of unlocking pathways to be—opening futures filled with possibility. Together, we’re on an ambitious journey toward enabling people living with mental health conditions to find clarity through self-discovery. Every journey needs a Compass.

MindMed is now Definium Therapeutics, a rebrand that reflects our commitment to forging a new era of psychiatry by applying precision to psychedelic medicine. Follow our new page at the link below!

MediPharm Labs was created in 2015 by a handful of industry experts in Ontario. With the medicinal benefits of cannabis firmly established – and with a global patient market demanding quality cannabis oil – MediPharm Labs was born. While initially exploring options to cultivate cannabis plant, MediPharm Labs came to recognize the opportunity for a select focus on cannabis concentrates. MediPharm Labs set out to master this area of production, and rely on the many cultivating experts to provide quality raw materials. In 2016, MediPharm labs submitted an application to Health Canada for approval to distribute medicinal cannabis oil. Proudly, MediPharm Labs was one of the first Licensed Producer applications in history to apply for license that did not include the cultivation of cannabis. The key to MediPharm Labs’ unrivaled quality is our best possible use of modern technology and innovative extraction techniques. MediPharm Labs produces cannabis oil that is pharmaceutical grade and and meets the specific quality and purity requirements. The team behind MediPharm Labs have proven industry experience in the areas of pharmaceutical extraction, processing and quality assurance. In 2018, MediPharm Labs is gearing up to commence distribution to our Health Canada approved business partners and make history. The response has been enormous, positive and heartening. Medicinal cannabis has arrived – and through our partners we will provide patients with access to pure, consistent and safe cannabis oil. MediPharm Labs commenced construction of a world-class extraction facility in Australia in June 2018. MediPharm Labs Australia is a subsidiary of MediPharm Labs Inc. and the companies’ first expansion outside of Canada. MediPharm Labs Australia completed its application process with the federal Office of Drug Control in February 2018 to extract and import medical cannabis products in Australia. For media and investor relations, please email: info@medipharmlabs.com